Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIVO
National Cancer Institute Sponsored Phase 1/1b clinical study to test combination of epigenetic and immune-oncology…
Cregis Shines at Paris Blockchain Week 2026, Accelerating European Expansion